Ipca Laboratories, a Rs.2,800 crore plus Mumbai pharma entity, has registered strong growth in consolidated net profit during third quarter ended December 2016 and its net profit increased by 57.2 per cent to Rs.41.38 crore from Rs.26.32 crore in the corresponding period of last year. EBDITA increased by 23.4 per cent to Rs.116.32 crore from Rs.94.29 crore. Its net sales increased by 8.3 per cent to Rs.731 crore from Rs.675 crore. With strong growth in profits, EPS moved up to Rs.3.28 from Rs.2.09 in the last period.

Its Indian formulations sales increased by 9 per cent to Rs.335 crore from Rs.308 crore and its formulations export moved up 3 per cent to Rs.233 crore from Rs.226 crore. APIs domestic sales increased by 23 per cent to Rs.34 crore from Rs.28 crore and APIs exports increased by 14 per cent to Rs.128 crore from Rs.112 crore.

For the nine months period ended December 2016, Ipca's standalone net sales increased by 11.7 per cent to Rs.2,442 crore from Rs.2,186 crore and its net profit went up sharply by 142 per cent to Rs.143.90 crore from Rs.59.58 crore in the same period of last year. Its formulations sales increased by 14 per cent to Rs.1,857 crore from Rs.1,631 crore and APIs sales increased by 4 per cent to Rs.548 crore from Rs.528 crore. Total exports moved up 11.2 per cent to Rs.1,213 crore from Rs.1,090 crore. Formulations exports amounted to Rs.772 crore as against Rs.679 crore in the last period.